Lexaria Bioscience Corp (LEXXW)

LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are act

New York, New York--(Newsfile Corp. - October 5, 2021) - PCG Digital -- Lexaria Bioscience Corp (NASDAQ: LEXX) is making headlines again this week. In a study conducted by a leading independent testing facility, DehydraTECH™ 2.0 nicotine pouches easily outperformed generic nicotine benzoate pouches, hitting peak delivery rates within eight minutes, and then again at thirty minutes. The generic pouches hit peak at forty-five minutes.It's a significant disparity when comparing two similar products

Vancouver, British Columbia--(Newsfile Corp. - September 23, 2021) - On Sat. Sept 25th at 5pm EST broadcast on FOX Business News - BTV-Business Television visits up-and-coming innovative investment opportunities.Discover Companies to Invest In - Watch their TV feature!Osisko Metals (TSXV: OM) (OTCQX: OMZNF) - As electric transportation rises in popularity, the zinc demand increases and Osisko is poised to take advantage with their advanced zinc projects.Fobi AI (TSXV: FOBI) (OTCQB: FOBIF) - BTV

New York, New York--(Newsfile Corp. - September 14, 2021) - PCG Digital -- The most recent results from HYPER-H21-2, a human clinical study of the effects of Lexaria's DehydraTECHTM-processed CBD on blood pressure (BP) over a 24-hour ambulatory period, have moved the needle significantly in Lexaria's path towards an eventual New Drug Application (NDA). As a precursor to that, the company has begun an Investigational New Drug (IND) enabling program.Volunteers for HYPER-H21-2 who cope ...

Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) - Lexaria Bioscience (NASDAQ: LEXX) - Lexaria Bioscience began developing DehydraTECH in 2014. Since then, they have strengthened and broadened the technology to an unprecedented degree.If you cannot view the video above, please visit: https://b-tv.com/investor-alert-lexaria-bioscience-the-modern-way-to-improve-oral-drugs/Lexaria Bioscience (NASDAQ: LEXX) Lexaria Bioscience is being featured on Bloomberg on Sept 6th to 10th, 2021,

Lexaria, delivering active ingredients to patients, could deliver for investors tooThe company that turns CBD into blood pressure control might be poised for a surgeTakeawaysOne critical component to over-the-counter drugs is how efficiently and how quickly (or not) they enter the bloodstream.Lexaria's DehydraTECHTM platform has proven to be an effective method to deliver active ingredients, with human tests demonstrating its ability with CBD as a hypertension treatment and animal tests demonstr